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Abstract
Background: Electrocardiography (ECG) has low sensitivity for detecting left ventricular hypertrophy (LVH), while
echocardiography cannot be routinely performed.
Design/methods: In this study we evaluate the prevalence of LVH and diastolic dysfunction in hypertensive patients
with normal ECG. We excluded patients with cardiovascular (CV) diseases, diabetes, chronic kidney disease, or pre-
senting ECG-LVH or other ECG anomalies. The enrolled 440 hypertensive patients underwent echocardiographic
examination (Acuson Sequoia 512); LV mass was indexed by body surface area (LVMI) and LVH was defined as LVMI
>125 g/m2 in men and >110 g/m2 in women. Diastolic function was evaluated by mitral inflow and tissue Doppler imaging
(TDI).
Results: The prevalence of LVH was 8.18% (95% confidence interval [CI] 5.97–11.1%). Multiple regression analysis
showed that the only variable independently associated with LVH was duration of hypertension (p< 0.001). The receiver
operating characteristic (ROC) curve showed that duration of hypertension was a powerful predictor of LVH, with an
area under the curve (AUC) of 0.878 and p< 0.0001. Further, in patients with LVH the mean difference of LVMI from the
cut-off value for LVH was 12.3 9.19 g/m2. Diastolic dysfunction, defined as early diastolic myocardial velocity (Em)
<0.08 m/s, was detected only in 3.2% of patients.
Conclusions: The prevalence of LVH among hypertensive patients with normal ECG, free of diabetes and of CV
diseases is low; moreover, patients with echocardiographic LVH presented LVMI values that identified mild LVH. Few
cases of impaired diastolic function were registered.
We suggest that in hypertensive patients with such characteristics the echocardiographic examination should be reserved
to those who present with higher duration of hypertension.
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Introduction
Early detection of left ventricular hypertrophy (LVH)
in hypertensive patients is of great importance for the
correct stratiﬁcation of cardiovascular (CV) risk,
because LVH is associated with increased CV events
and mortality.1
Electrocardiography (ECG) has the advantages of
low costs, simplicity and almost ubiquitous diﬀusion;
LVH detected by the Sokolow–Lyon index
(SV1þRV5–6 >38mm) or by the Cornell voltage
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QRS duration product (>2440mm*ms) is an independ-
ent predictor of CV events,2,3 and ECG can also be
used to detect patterns of ventricular overload or
‘strain’ (known to indicate more severe risk),2 ischae-
mia, conduction defects and arrhythmias. However, it
is well known that the sensitivity of ECG to detect LVH
is low, independently of the deﬁnition of LVH.4
Echocardiography is more sensitive than ECG in
diagnosing LVH and predicting CV risk, and may
help in the more precise stratiﬁcation of overall risk
and in the determination of therapy.5,6
Nevertheless, the routine execution of echocardio-
graphic examination in hypertensive patients, although
useful on various grounds, may lead to some diﬃcul-
ties. The correct indication to echocardiography in
hypertensive patients is still a matter of debate for sev-
eral reasons (very high number of patients, cost, avail-
ability), particularly in untreated hypertensive patients
at low or medium risk.
The aim of this study is to evaluate the prevalence
and the predictors of LVH and the prevalence of
anomalies of diastolic function in a group of hyperten-
sive patients with normal ECG and free of diabetes and
CV diseases.
Patients and methods
In accordance with the Declaration of Helsinki and
institutional guidelines, the protocol was approved by
the local Ethical Committee and subjects were aware of
the investigational nature of the study and agreed to
participate after informed consent.
Study population
The patients were selected among the subjects consecu-
tively attending our Internal Medicine, Nephrology and
Hypertension Unit. All subjects underwent a detailed
review of their medical history and routine laboratory
measurements.
The deﬁnition of hypertension was based on the
2007 European Society of Hypertension/European
Society of Cardiology (ESH/ESC) Guidelines.5 Clinic
blood pressure (BP) was considered as the average of
three consecutive measurements using a mercury sphyg-
momanometer after the subjects had been supine for 5
minutes.
Glomerular ﬁltration rate (GFR) was estimated
using Cockcroft and Gault equation,7 corrected by
body surface area.
The following exclusion criteria were applied:
– age <20 or >75 years;
– diabetes;
– chronic kidney disease (CKD);8
– anomalies of ECG;
– history of CV diseases (previous coronary artery dis-
ease, history of angina or myocardial infarction,
abnormalities of cardiac rhythm, heart failure, ejec-
tion fraction <55%, moderate or severe valvular dis-
eases, previous transient ischaemic attack or stroke);
– other major non-CV diseases.
After the application of the exclusion criteria, 440
White hypertensive subjects with normal ECG were
included in the study.
Laboratory methods
Determination of routine biochemical parameters was
performed with standard techniques by using an auto-
analyser (Boehringer Mannheim for Hitachi system
911, Germany).
Electrocardiography
ECG was performed with a standard 12-lead system
with the patient at rest in supine position.
ECG was deﬁned as normal when the following con-
ditions were simultaneously present:
– sinus rhythm;
– absence of conduction abnormalities;
– absence of LVH with Sokolow–Lyon index, Cornell
voltage criteria and Cornell voltage QRS duration
product;
– absence of left atrial abnormalities;
– absence of ST trait or T-wave abnormalities.
Echocardiography
The echocardiographic examination was executed by
using an Acuson Sequoia 512 system (Siemens,
Mountain View, CA, USA). Images were taken in left
lateral decubitus position. Two-dimensional targeted
M-mode echocardiography was performed by using
the parasternal long-axis acoustic window in order to
evaluate left ventricular end-diastolic diameter
(LVEDD), left ventricular end-systolic diameter
(LVESD), interventricular septum thickness (IVST),
and posterior wall thickness (PWT) according to the
American Society of Echocardiography (ASE)
recommendations.9
Only those frames with optimal visualization of
interfaces and showing simultaneous visualization of
septum, left ventricular diameters and posterior wall
were used for readings.
Left ventricular mass (LVM) was determined by
using the ASE-corrected cube formula10 and was
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indexed by body surface area (LVMI). In our labora-
tory, the mean intra-observer variability for LVM
was 8.6%.
LVH was deﬁned as LVMI >125 g/m2 in men and
>110 g/m2 in women, as suggested by the 2007 ESH/
ESC Guidelines.5 LVMI was used to divide the study
population into two subgroups (with and without
LVH) and in the main statistical analyses of the results.
The prevalence of LVH was also evaluated indexing
LVM by height elevated by a power of 2.7 (LVMH2.7),
in order to provide a more stringent allowance for those
who were overweight.11 In that case LVH was deﬁned
as LVMH2.7 >51 g/m2.7 in both sexes.
Relative wall thickness (RWT) was calculated as the
ratio of 2PWT/LVEDD. Concentric and eccentric LVH
were deﬁned on the basis of RWT above or below 0.45,
respectively.
Left ventricular ejection fraction (EF) was assessed
by 2D-echo using modiﬁed Simpson’s rule.12
Diastolic function was evaluated by using both
mitral inﬂow and tissue-Doppler echocardiography,
performed according to the ASE recommendations.13
Mitral inﬂow was assessed in the apical four-chamber
view, using pulsed-wave Doppler echocardiography,
with the Doppler beam aligned parallel to the direction
of ﬂow and the sample volume at the leaﬂet tips. From
the mitral inﬂow proﬁle, the E-wave (E) and A-wave
(A) peak velocities, E/A ratio and E-deceleration time
(DT) were measured. Isovolumic relaxation time
(IVRT) was calculated between the aortic valve closure
and the start of E-wave.
Tissue Doppler imaging (TDI) of the mitral annulus
was obtained from the apical four-chamber view, using
a 1- to 2-mm sample volume placed in the lateral mitral
valve annulus, in order to evaluate early diastolic myo-
cardial velocity (Em).
We decided to evaluate diastolic function principally
by means of TDI because parameters measured by TDI
are more preload-independent than those calculated by
mitral inﬂow;14 further, Em is inversely related to myo-
cardial ﬁbrosis.14
Echocardiographic data are expressed as the average
of ﬁve consecutive cardiac cycles. Images were read by
a single cardiologist, who was blinded to the patient’s
clinical characteristics.
Statistics
Data for continuous variables are given as
means standard deviation (SD).
Diﬀerences between groups were evaluated by
using the independent-sample Student’s t-test with
Bonferroni correction, for continuous variables, and
the chi-squared (2) test, with Yates’ correction, for
the categorical variables.
The independent correlates of LVH were tested by
means of multivariate stepwise logistic regression ana-
lysis by calculating odds ratios and 95% conﬁdence
intervals (CI).
Receiver operator characteristic (ROC) curves were
built to assess the power of independent correlates of
LVH to predict it.
The null hypothesis was rejected at a two-tailed
p 0.05.
The statistical analyses were performed by using the
SYSTAT DATA software package, version 5.2 (Systat,
Evanston, IL, USA).
Results
The main demographic and clinical data of the patients
are synthesized in Table 1. Patients with LVH were
Table 1. Principal demographic and clinical data (mean standard deviation) of the whole study population and of the subgroups of
patients with and without left ventricular hypertrophy
Whole sample (n¼ 440) LVHþ (n¼ 36) LVH (n¼ 404)
Age, years 48.3 15 53.9 11 47.1 12.7*
Males/Females 268/172 16/20 252/152
Body mass index, Kg/m2 27.7 4.5 27.6 4.2 27.7 3.2
HbA1c, % 5.3 0.3 5.2 0.2 5.3 0.2
Serum Creatinine, mmol/l 78.67 12.3 78.68 14.1 77.8 13.2
GFR, ml/min/1.73 m2 116 24 115 21.7 116.2 22
Haemoglobin, g/l 132 12 131 11 133 10
Systolic blood pressure, mmHg 134.5 4.6 135 7.1 134.2 13
Diastolic blood pressure, mmHg 81 11.7 77.8 7.1 81.7 12.9**
Known duration of hypertension, months 52.54 69.04 130.66 83.66 45.84 63.47
GFR, glomerular filtration rate estimated by the Cockcroft–Gault equation. *p¼ 0.002 **p< 0.0001 vs. group LVH þ.
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older and presented with longer duration of hyperten-
sion, while the subgroups with and without LVH did
not diﬀer with regards to gender, body mass index,
renal function, or blood pressure.
Table 2 shows the main echocardiographic ﬁndings.
Patients with LVH showed signiﬁcantly higher LV wall
thicknesses, LV diameters, RWT, and left atrium
diameter.
Diastolic function, evaluated by both mitral inﬂow
and TDI, was signiﬁcantly worse in patients with LVH.
Prevalence of LVH
Out of the 440 patients, 36 (8.18%) presented LVH; of
them, 28 patients (77.7%) had concentric LVH and 8
had eccentric LVH. Limiting the analysis to each
gender, results were the following: 16 out of the 268
males (5.97%) and 20 out of the 172 females
(11.63%) had LVH (Figure 1). Among the patients
with LVH, the concentric pattern was highly prevalent:
75% in males and 80% in females.
The mean (SD) value of LVMI was 92.3 17 g/m2
in the whole group and 132.4 11.3 g/m2 in the sub-
group with LVH (135.5 7.84 g/m2 in males and
123.8 10.1 g/m2 in females with LVH).
Moreover, in patients with LVH we evaluated the
mean diﬀerence of the values of LVMI from the cut-
oﬀ value for LVH. This diﬀerence was 12.3 9.19 g/m2
in the whole group, 10.5 7.84 g/m2 in males, and
13.8 10.1 g/m2 in females (Figure 1).
The mean ( SD) value of LVMH2.7 was
42.93 9.9 g/m2.7 in the whole sample, 62.4 7.17 g/
m2.7 in patients with LVH, and 40.09 6.53 g/m2.7 in
those without LVH (p< 0.0001). With this indexation
of LVM, the prevalence of LVH was 12.27% (95% CI
9.5–15.7%) in the whole group, 12.7% (95% CI 9.2–
17.2%) in males and 11.63% (95% CI 7.65–17.3%) in
females.
Predictors of LVH in patients with normal ECG
Multivariate stepwise logistic regression analysis, con-
ducted in the whole study population, showed that the
only variable independently correlated with the pres-
ence of LVH was known duration of hypertension
(odds ratio 1.015, 95% CI 1.011–1.019, p¼ 0.0001).
The other covariates included in the analysis were:
age, sex, body mass index, and systolic blood pressure.
Further, the ROC curve showed that known dur-
ation of hypertension was also a powerful predictor
of the presence of LVH, with AUC of 0.878 and
p< 0.0001 (Figure 2). In particular, a known duration
of hypertension >66 months had 89.74% sensitivity
and 80.5% speciﬁcity to detect LVH.
Diastolic function
Diastolic dysfunction, deﬁned as Em <0.08m/s, was
found only in 14/440 patients (3.18%). Among these
14 patients (8 males and 6 females), 8 had LVH, all
with concentric pattern (5 males and 3 females).
Discussion
Our study was aimed at evaluating the prevalence of
LVH and diastolic dysfunction in a group of hyperten-
sive patients with normal ECG and free of diabetes,
CKD and CV diseases.
Table 2. Echocardiographic data (mean standard deviation) of the whole study population and of the subgroups of patients with
and without left ventricular hypertrophy
Whole sample (n¼ 440) LVHþ (n¼ 36) LVH (n¼ 404)
Left ventricular end-diastolic diameter, mm 48.5 3.9 51.1 3 48.5 3.5*
Left ventricular end-systolic diameter, mm 29.8 4.2 32.3 2 30.3 3.3 **
Ejection fraction, % 64.6 3.4 62.8 3.1 64.6 3.3
Interventricular septum thickness, mm 9.94 1.3 11.9 0.7 9.94 1.1*
Posterior wall thickness, mm 9.77 1.3 11.9 0.8 9.77 1.1*
LVMI, g/m2 92.3 17 132.4 11.3 92.3 15.4*
Relative wall thickness 0.40 0.05 0.46 0.04 0.4 0.04*
Left atrium diameter, mm 35 3.8 37.5 3.5 34.9 3.7**
E/A 1.19 0.38 0.90 0.18 1.19 0.38*
DT, m/s 216 43 254 61 217 39*
IVRT, m/s 84 16 98 14 84 16*
Em, m/sec 0.18 0.06 0.128 0.04 0.18 0.05*
LVMI, left ventricular mass indexed by body surface; E, E-wave peak velocity; A, A-wave peak velocity; DT, E-wave deceleration time; IVRT, isovolumic
relaxation time; Em, early diastolic myocardial velocity. *p< 0.0001 **p¼ 0.002 vs. group LVH þ.
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The main ﬁndings of our study are the following:
– in this sample of low/medium-risk patients the
prevalence of LVH was low (8.18% using LVMI,
12.27% using LVMH2.7), particularly in males;
– the values of LVMI in patients with LVH were only
a little above the cut-oﬀ values that deﬁne the pres-
ence of LVH;
– the presence of LVH was signiﬁcantly associated
with and predicted by the duration of hypertension;
– the prevalence of diastolic dysfunction was low
(3.18%).
These results suggest that the execution of an echo-
cardiographic examination in hypertensive patients
with normal ECG may not be very useful or cost/
time-eﬀective if routinely performed, due to the low
probability of identifying subjects with LVH or
improving the stratiﬁcation of CV risk and the treat-
ment approach.
However, the examination should be reserved for
patients with longer duration of hypertension; our
data show that in hypertensive patients with normal
ECG and free of other associated pathological condi-
tions, a useful threshold to decide whether performing
the examination or not may be duration of hyperten-
sion longer than 5 years.
The routine execution of echocardiography in hyper-
tensive patients, in fact, is a matter of debate. In the
ESH/ESC Guidelines5 echocardiography is presented
as a second-level examination, to be performed only
when and where the local conditions are adequate.
A recent Italian multicentre survey showed that
hypertension accounts for approximately 30% of echo-
cardiographic examinations currently performed in
outpatient hospital or academic echo laboratories.15
In a study by Cuspidi et al.,16 580 never-treated patients
with grade 1–2 hypertension, free of diabetes, CV dis-
eases, renal insuﬃciency and ECG-LVH, underwent
echocardiography. LVH registered an overall preva-
lence of only 14.8%. Since in the subgroup of age
<50 years echocardiography had a very limited
impact on risk stratiﬁcation and too high costs, the
authors concluded that the search for LVH by echocar-
diography in order to improve CV risk stratiﬁcation
could be optimized on the basis of demographic
variables.
Our results are consistent with those of Cuspidi
et al.;16 in our sample of hypertensive patients the
prevalence of LVH detected by echocardiography was
low (8.18%). Moreover, LVMI values generally identi-
ﬁed mild LVH, which only in very few cases was
accompanied by alterations of LV diastolic function
detected by TDI.
An objection to a limited use of echocardiography in
hypertension could be the fact that one of our aims is
an early detection of target-organ damage, and in fact
ECG is not suﬃciently sensitive at detecting mild initial
forms of left ventricular growth such as LV remodel-
ling. Nevertheless, we should also bear in mind that the
treatment of these forms, often having no functional
abnormality, is not substantially diﬀerent from the
treatment of hypertensive patients without LVH.
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Figure 1. (a) Prevalence of left ventricular hypertrophy in the
whole study population and by gender. (b) Mean difference of the
values of left ventricular mass indexed by body surface area
(LVMI) from the cut-off value for left ventricular hypertrophy
(LVH) in patients with LVH, overall and by gender. 95%
confidence intervals (CI) are reported in parentheses.
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Figure 2. Receiver operating characteristic (ROC) curve for
the detection of left ventricular hypertrophy (LVH). Known
duration of hypertension >66 months had 89.74% sensitivity and
80.5% specificity to detect LVH. AUC, area under the curve.
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The proposal, advanced both in the past and
recently, of a limited echocardiographic examin-
ation,17,18 performed to detect only some parameters,
does not appear as an adequate solution and did not
meet with good success, since it does not really shorten
the execution time of the examination and entails the
loss of very important information (diastolic function).
On the other hand, it is reasonable that echocardi-
ography should be always performed when other
pathological conditions are associated with the
‘simple’ hypertension. For example, diabetes or CKD
are frequently associated with LV structural and func-
tional changes.19–21
Moreover, we think that the execution of the echo-
cardiographic examination should be recommended if
ECG is positive for LVH (Sokolow–Lyons index or
Cornell voltage QRS duration product and/or strain
pattern): in this case we should not consider echocardi-
ography as a simple duplication or a means to conﬁrm
LVH detected by ECG, because it is also possible to
quantify LVH, obtain information on geometric
changes (concentric or eccentric LVH), evaluate systolic
and diastolic function22 (the latter is often not normal),
and receive more accurate prognostic information.
Finally, in this study we mainly used LVMI to evalu-
ate the prevalence and the predictors of LVH, and
LVMH2.7 was utilized only as a conﬁrmation of the
prevalence found by using LVMI. In this regard, we
should point out that the LVMI and the cut-oﬀs for
LVH we used (>125 g/m2 in men and >110 g/m2 in
women), are the methods suggested by ESH/ESC
Guidelines. The best method for the normalization of
LVM measurements in adults is still a matter of debate,
and diﬀerent studies agree on the conclusion that the
method of indexing LVM does not have a signiﬁcant
impact on the ability to predict CV risk.23–25 Finally,
the choice of a diﬀerent indexation method does not
inﬂuence the low prevalence of diastolic dysfunction
found in this study.
Conclusions
In summary, since it is not possible to perform an echo-
cardiographic examination in all hypertensive patients,
it seems reasonable to recommend the examination on
the basis of a clinically oriented approach (Figure 3).
Thus, hypertensive patients with normal ECG and
without other pathological conditions should receive
an echocardiographic examination not routinely, but
on the basis of clinical variables such as known dur-
ation of hypertension. Hypertensive patients who do
not undergo echocardiography should repeat ECG
(for example, once a year) and undergo the examin-
ation in the case of new changes of ECG (QRS, ST
segment), or in the case of symptoms of left ventricular
dysfunction (dyspnoea, oedema).
Acknowledgements
Preliminary results of this work were presented as oral com-
munication at the 21st European Meeting on Hypertension
and Cardiovascular Prevention (Milan, 17–20 June 2011).
The authors are grateful to Dr Roberto Palermo for language
editing.
Funding
This work was in part supported by a grant from the Italian
‘Ministero dell’Istruzione, dell’Universita` e della Ricerca’
(MIUR).
Positive
or
negative with hypertension >5 years
Hypertension
Positive
Follow up
(ECG-Clinical evaluation)
Normal EchoPathological Echo
Follow up*
Echo
ECG
Negative with hypertension <5 years
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